OXFORD,
England, Sept. 3, 2024 /PRNewswire/ -- Caristo
Diagnostics, a global leader in cardiovascular disease
diagnostics and risk prediction, has been selected as a
quarterfinalist for the prestigious Digital Health Hub
Foundation: Digital Health Awards. Caristo was chosen as a
quarterfinalist for the Rising Star Provider Diagnostics
Category.
This recognition highlights the company's
dedication in creating a new paradigm to prevent
heart attacks and fight cardiac disease by uncovering hidden
inflammation. The Digital Health Awards honor organizations making
strides in improving healthcare efficiency, effectiveness and
equity with their digital innovations. As a quarterfinalist,
Caristo stands out for its commitment to applying advanced AI
technology to cardiovascular disease diagnosis, supporting
healthcare professionals to stratify and treat coronary artery
disease, the world's No. 1 killer.
"We are deeply honored to be named a
quarterfinalist in the Provider Diagnostics category of the Digital
Health Awards," said Frank Cheng,
CEO of Caristo. "This recognition reflects not only our dedication
to improving heart health, but the actual positive outcomes our
clients have achieved taking advantage of our technologies."
Out of a substantial pool of over 1,500 submissions, only the
most promising 15 quarterfinalists per category, per track have
advanced to this stage.
A recent study published in The
Lancet (May 29th)
revealed that today's focus on diagnosing and treating obstructive
coronary artery disease misses two-thirds of fatal and non-fatal
cardiac events. By measuring coronary inflammation, Caristo's
proprietary CaRi-Heart technology is uniquely able to uncover this
hidden, but treatable, driver of disease progression.
CaRi-Heart technology is commercially available in the European
Union, the United Kingdom, and
Australia and is currently seeking
US Food & Drug Administration clearance.
"This year has set a new benchmark for excellence, with a
remarkable influx of global submissions showcasing groundbreaking
innovations in digital health. The level of ingenuity and
commitment we've seen is truly inspiring. Congratulations to all of
our quarterfinalists for their outstanding achievements," said
Mark Goldstein, Chairman of the
Digital Health Hub Foundation.
Finalists will be announced September 22, 2024 and the winners will be
announced at the Grand Finale taking place at HLTH on October 21, 2024.
About Caristo Diagnostics
Caristo Diagnostics is a global leader in cardiac
and vascular disease diagnostics and risk prediction. Founded in
2018 as a spin-out company from the University
of Oxford, the world's #1 research university, Caristo has
developed a portfolio of imaging-based and AI-assisted platforms
that can be applied to aid the prediction and diagnosis of heart
attack, stroke, and diabetes. Caristo has been recognized by
Newsweek as one of the best digital health companies,
and highlighted by Nature as
one of the most exciting
science-based companies to have emerged from
academic labs. Find Caristo online on its website,
LinkedIn and X.
About Digital Health Hub Foundation:
Our mission is to help the world's next best innovative
healthcare companies scale and grow. Founded in 2017, on the campus
of UCSF in San Francisco, our now
30,000 member community consists of thousands of early-to
late-stage healthcare companies and highly qualified healthcare
industry providers, payors, experts, mentors, investors, clinicians
and researchers who participate in our annual awards ceremony where
we bring together the industry to honor and validate the best of
the best and celebrate the technological advances in healthcare and
the impact it has.
Logo -
https://mma.prnewswire.com/media/2054669/4888016/Caristo_Logo.jpg
Contact
Frank Cheng,
Caristo Diagnostics CEO
info@caristo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caristo-diagnostics-recognized-as-quarterfinalist-in-the-digital-health-awards-rising-star-category-302236692.html
SOURCE Caristo Diagnostics